Real-world Outcomes of the PreserFlo® MicroShunt in Glaucoma Patients

Authors: Nimrod Dar , Chris Rudnisky, Sylvia Chen, Michael Dorey. University of Alberta.

Author Disclosures: N. Dar: None. C. Rudnisky: None. S. Chen: None. M. Dorey: None. 
 

Abstract Body: 

Purpose: To evaluate the efficacy and safety of the PreserFlo® MicroShunt glaucoma device in patients with glaucoma. 

Study Design: A single-center retrospective cohort study. 

Methods: Records of consecutive patients that underwent PreserFlo® MicroShunt implantation were reviewed. The main outcome measure was surgical success. Intraocular pressures (IOP), and IOP lowering medication use were secondary outcome measures. Success was defined by IOP between 6 and 17 mmHg or <20% reduction in IOP without medications (criterion A) or IOP between 6 and 14 mmHg (criterion B) for both complete (no medications) and qualified (with medications). 

Results: 120 eyes of 106 patients with preoperative median IOP of 20.0 mmHg (IQR 17.0-24.0) on three (IQR 2-4) medications were included. Postoperative median IOP was 10.0 mmHg (IQR 7.0-12.0) on one (IQR 0-3) medication at six months. Qualified and complete success rates (95% CI) at 6 months were 92% and 70% for criterion A and 83% and 68% for criterion B. Complications were transient hyphema, choroidal detachment and hypotony maculopathy, with 2.4% of patients undergoing reoperation. 

Conclusions: With promising success rates, reduced medication use, and good safety profile, Preserflo® MicroShunt can be a viable surgical option for glaucoma patients